On Friday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) opened lower -3.28% from the last session, before settling in for the closing price of $12.20. Price fluctuations for DAWN have ranged from $11.94 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 68.60% at the time writing. With a float of $72.64 million, this company’s outstanding shares have now reached $100.81 million.
Let’s look at the performance matrix of the company that is accounted for 155 employees. In terms of profitability, gross margin is 97.37%, operating margin of -206.27%, and the pretax margin is -81.57%.
Day One Biopharmaceuticals Inc (DAWN) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Day One Biopharmaceuticals Inc is 27.97%, while institutional ownership is 81.28%. The most recent insider transaction that took place on Dec 10 ’24, was worth 399,339. In this transaction HEAD OF R&D of this company sold 30,000 shares at a rate of $13.31, taking the stock ownership to the 1,034,015 shares. Before that another transaction happened on Nov 18 ’24, when Company’s CHIEF EXECUTIVE OFFICER sold 10,554 for $13.21, making the entire transaction worth $139,420. This insider now owns 108,377 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.60% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Check out the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). In the past quarter, the stock posted a quick ratio of 14.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) saw its 5-day average volume 0.79 million, a negative change from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 11.38%. Additionally, its Average True Range was 0.52.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 4.06%, which indicates a significant decrease from 12.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.20% in the past 14 days, which was lower than the 36.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.57, while its 200-day Moving Average is $14.24. Nevertheless, the first resistance level for the watch stands at $12.14 in the near term. At $12.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.76. If the price goes on to break the first support level at $11.52, it is likely to go to the next support level at $11.25. Assuming the price breaks the second support level, the third support level stands at $10.90.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are currently 100,846K shares outstanding in the company with a market cap of 1.19 billion. Presently, the company’s annual sales total 0 K according to its annual income of -188,920 K. Last quarter, the company’s sales amounted to 93,760 K and its income totaled 37,040 K.
